Canadian Rheumatology Association Recommendations for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis

• Published in: Journal of rheumatology Vol. 50; no. 3; p. 390
• Main Authors: Berard, Roberta, Ng, Hon Yan, Human, Andrea, Piskin, David, Dhalla, Muhammed, Gottlieb, Chloe, Batthish, Michelle, Chédeville, Gaëlle, Forest, Christina, Fortin, Eric, Gardiner, Jane, Gerhold, Kerstin, Jastrzebski, Andre, Lang, Bianca, Miettunen, Paivi M H, Morgenstern, Sabrina, Morin, Marie-Paule, Rosenberg, Alan, Rumsey, Dax G, Solarte, Carlos E, Tehrani, Nasrin, Duffy, Karen Watanabe, Pardo, Jordi Pardo, Hazlewood, Glen S, Levy, Deborah M
• Format: Journal Article
• Language: English
• Published: Canada 01.03.2023
• Subjects: Arthritis, Juvenile - diagnosis; Canada; Child; Humans; Rheumatology; Uveitis - complications; Canada; guidelines; juvenile idiopathic arthritis; evidence-to-decision framework; GRADE-ADOLOPMENT; chronic anterior uveitis
• ISSN: 0315-162X
• DOI: 10.3899/jrheum.220261

To develop Canadian recommendations for the screening, monitoring, and treatment of uveitis associated with juvenile idiopathic arthritis (JIA). Recommendations were developed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-ADOLOPMENT approach. A working group of 14 pediatric rheumatologists, 6 ophthalmologists, 2 methodologists, and 3 caregiver/patient representatives reviewed recent American College of Rheumatology (ACR)/Arthritis Foundation (AF) recommendations and worked in pairs to develop evidence-to-decision (EtD) tables. A survey to assess agreement and recommendations requiring group discussion was completed. EtD tables were presented, discussed, and voted upon at a virtual meeting, to produce the final recommendations. A health equity framework was applied to all aspects of the adolopment process including the EtD tables, survey responses, and virtual meeting discussion. The survey identified that 7 of the 19 recommendations required rigorous discussion. Seventy-five percent of working group members attended the virtual meeting to discuss controversial topics as they pertained to the Canadian environment, including timing to first eye exam, frequency of screening, escalation criteria for systemic and biologic therapy, and the role of nonbiologic therapies. Equity issues related to access to care and advanced therapeutics across Canadian provinces and territories were highlighted. Following the virtual meeting, 5 recommendations were adapted, 2 recommendations were removed, and 1 was developed de novo. Recommendations for JIA-associated uveitis were adapted to the Canadian context by a working group of pediatric rheumatologists, ophthalmologists with expertise in the management of uveitis, and parent/patient input, taking into consideration cost, equity, and access.